Caris Life Sciences
Caris Life Sciences is a major precision oncology diagnostics provider focused on advanced molecular profiling, tumor characterization, and data-driven cancer care. The company provides laboratory testing, tumor profiling, and blood-based cancer diagnostics designed to support precision oncology.
- Highest 2026 tier: Tier I
- Precision Medicine Diagnostics Providers
- 2 ranking categories
Overview
Caris Life Sciences is a major precision oncology diagnostics provider focused on advanced molecular profiling, tumor characterization, and data-driven cancer care. The company provides laboratory testing, tumor profiling, and blood-based cancer diagnostics designed to support precision oncology.
Caris describes its mission as fulfilling the promise of precision oncology through advanced laboratory testing, including tumor profiling and blood-based cancer diagnostics. Its platform is also supported by research collaborations through the Caris Precision Oncology Alliance, with Caris and collaborators presenting broad oncology research across multiple tumor types.
Caris Life Sciences is included in 2 2026 ranking categories. Its highest classification is Tier I. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | Caris Life Sciences |
| Founded | 2008 |
| Institution type | Precision Medicine Diagnostics Providers institution |
| Headquarters | Irving, United States |
| Primary focus | Precision Medicine Diagnostics Providers |
| Highest 2026 ranking tier | Tier I |
Principal activities
Caris describes its mission as fulfilling the promise of precision oncology through advanced laboratory testing, including tumor profiling and blood-based cancer diagnostics. Its platform is also supported by research collaborations through the Caris Precision Oncology Alliance, with Caris and collaborators presenting broad oncology research across multiple tumor types.
Core capability
Precision Medicine Diagnostics Providers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Precision Medicine Diagnostics Providers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
Caris’ advanced tumor profiling, blood-based diagnostics, precision oncology network, and AI-oriented platform support its position as one of the leading providers in this category.
Caris Life Sciences is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier I.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Caris Life Sciences should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Caris Life Sciences. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Caris Life Sciences |
| Headquarters | Irving, United States |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Precision Medicine Diagnostics Providers 2026 — 2026 inclusion and tier classification.
- Healthcare Ranking — Top 30 Genetic Testing & Genomics Providers 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
